This is a news story, published by Yahoo Finance, that relates primarily to Verzenio news.
For more Verzenio news, you can click here:
more Verzenio newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Eli Lilly stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest soaring pharma stock news, pharma stock news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Lilly stockThe Motley Fool
•74% Informative
Eli Lilly's Mounjaro is now Lilly 's top-selling product.
Sales for cancer drug Verzenio jumped 40% year over year in Q1 .
Lilly has high hopes for donanemab in treating Alzheimer's disease.
Analyst think that mirikizumab could achieve peak annual sales of up to $2 billion .
VR Score
67
Informative language
62
Neutral language
18
Article tone
formal
Language
English
Language complexity
40
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
7
Source diversity
2
Affiliate links
no affiliate links